33 completed, 23 recruiting, 19 unknown, 7 active not recruiting. 13 Not applicable, 9 Phase 4, 7 Phase 2, 6 Phase 3, 1 Phase 1.
Follow Severe Asthma: new trials by email Literature Review of Severe Asthma trials Research Report on Severe Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Educational Needs of Patients With Severe Asthma on Targeted Immunotherapies Initial assesment interwiew, Intake Interview with the Patient - Severe Asthma | Not yet recruiting | University Hospital, Angers | 20 | 2027-01-04 | 2026-10-02 | |
| Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP) | Not yet recruiting | AstraZeneca | 210 | 2026-11-28 | 2026-06-04 | |
| COINCIDE: Cardineurovascular dIsease and Obstructive Airway Disease Routine Clinical Care - Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma | Not yet recruiting | VASCage GmbH | 350 | 2026-10-15 | 2026-10-09 | |
| Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis Tezepelumab - Allergic Bronchopulmonary Aspergillosis, Severe Asthma | Not applicable | Not yet recruiting | Qianfoshan Hospital | 10 | 2026-09-01 | 2026-08-11 |
| Physical Activity Promotion and Clinical Remission in Severe Asthma Physical activity promotion, Tezepelumab - Severe Asthma | Not applicable | Recruiting | University of Leeds | 140 | 2026-07-31 | 2026-08-17 |
| A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma Frevecitinib, Placebo - Severe Asthma | Phase 2 | Recruiting | Kinaset Therapeutics Inc | 512 | 2026-07-16 | 2026-07-28 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) Tezepelumab, Placebo - Severe Asthma | Phase 4 | Recruiting | University of Alberta | 100 | 2026-05-11 | 2026-07-17 |
| Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes Tapering of inhaled corticosteroid (ICS) treatment - Severe Asthma | Enrolling by invitation | Franciscus Gasthuis | 61 | 2026-05-01 | 2026-07-21 | |
| Execise Intervention in Adult Severe Asthma Exercise intervention - Severe Asthma, Asthma | Not applicable | Recruiting | Helsinki University Central Hospital | 60 | 2026-03-18 | 2026-06-17 |
| Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab Tezepelumab - Severe Asthma | Phase 3 | Recruiting | AstraZeneca | 400 | 2026-01-28 | 2026-09-03 |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | Generate Biomedicines | 786 | 2026-01-20 | 2026-10-20 |
| Remission in Adults With Severe Asthma in Thailand Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Spirometry, Fractional exhaled nitric oxide (FeNO) test - Severe Asthma, Asthma Control Level | Recruiting | Thammasat University | 230 | 2026-01-01 | 2026-04-17 | |
| Withdrawal of Dupilumab in Severe Asthma Stopping dupilumab - Severe Asthma | Phase 4 | Recruiting | University Hospital, Toulouse | 205 | 2025-12-15 | 2026-10-08 |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) GB-0895, Placebo - Severe Asthma | Phase 3 | Recruiting | Generate Biomedicines | 786 | 2025-12-03 | 2026-10-22 |
| Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma Hyperpolarized Xenon 129 - Severe Asthma | Recruiting | Bastiaan Driehuys | 5 | 2025-11-17 | 2025-11-20 | |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis Fasenra - Allergic Bronchopulmonary Aspergillosis, Severe Asthma | Recruiting | Qianfoshan Hospital | 20 | 2025-09-01 | 2026-04-21 | |
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites | Phase 3 | Not yet recruiting | University Hospital, Montpellier | 38 | 2025-07-15 | 2025-06-10 |
| Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease Hyperpolarized 129 Xenon - Severe Asthma, COPD | Recruiting | University of Kansas Medical Center | 8 | 2025-06-01 | 2026-07-01 |
Showing 20 of 95. Sign in to see all of them.
Asthma (95) · Pulmonary Eosinophilia (8) · Aspergillosis, Allergic Bronchopulmonary (4) · Lymphoma, Follicular (4) · Pulmonary Disease, Chronic Obstructive (4) · Bronchial Diseases (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Angioedema (1) · Arthritis, Psoriatic (1) · Behcet Syndrome (1) · Cardiovascular Diseases (1) · Churg-Strauss Syndrome (1) · Cystic Fibrosis (1) · Depression (1)
Hypersensitivity, Immediate (95) · Immune System Diseases (95) · Lung Diseases, Obstructive (95) · Respiratory Hypersensitivity (95) · Hypersensitivity (94) · Bronchial Diseases (93) · Lung Diseases (93) · Respiratory Tract Diseases (93) · Hemic and Lymphatic Diseases (12) · Eosinophilia (8) · Hematologic Diseases (8) · Hypereosinophilic Syndrome (8) · Leukocyte Disorders (8) · Pathological Conditions, Signs and Symptoms (6) · Lymphatic Diseases (5)
tezepelumab (8) · mepolizumab (6) · benralizumab (4) · Blood Specimen Collection (3) · Biopsy (2) · dupilumab (2) · Albuterol (1) · Bariatric Surgery (1) · Biological Products (1) · Bronchial Thermoplasty (1) · Bronchoalveolar Lavage (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Escitalopram (1) · Focus Groups (1)
AstraZeneca (19) · Assistance Publique - Hôpitaux de Paris (6) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Generate Biomedicines (2) · Qianfoshan Hospital (2) · Royal Devon and Exeter NHS Foundation Trust (2) · University Hospital, Montpellier (2) · University Hospital, Toulouse (2) · Upstream Bio Inc. (2) · Aristotle University Of Thessaloniki (1) · Asan Medical Center (1) · Assistance Publique Hopitaux De Marseille (1) · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · Bastiaan Driehuys (1)
France (16) · United States (15) · United Kingdom (13) · Italy (11) · Spain (10) · Netherlands (8) · Canada (7) · Belgium (6) · China (6) · Germany (6) · Argentina (5) · Bulgaria (5) · Chile (4) · Czechia (4) · Greece (4)
Justin Salciccioli, MD (2) · Matthew Masoli, MD (2) · Adelmir Machado, MD (1) · Adriano Vaghi, MD (1) · Alberto Cukier, M/D (1) · Alcindo Cerci Neto, MD (1) · Ana Mendes (1) · Andrea Matucci, MD (1) · Andrey S Belevskiy, Ph.D. (1) · Anke-Hilse Maitland-van der Zee, Prof.Dr. (1) · Antonino Musarra, MD (1) · Berta Ruiz-Leon, MD., Ph.D. (1)
PMID 10109801, PMID 11549526, PMID 12480423, PMID 15823451, PMID 16226443, PMID 16478839, PMID 17360725, PMID 20688929, PMID 21893215, PMID 22857879, PMID 23471469, PMID 24232701, PMID 25441637, PMID 26337607, PMID 26487563, PMID 27239557, PMID 27820746, PMID 27852260, PMID 28137489, PMID 28433687, PMID 28500390, PMID 28583260, PMID 28684597, PMID 28769983, PMID 28960335, PMID 29290515, PMID 29340498, PMID 29453280, PMID 29782217, PMID 29782224, PMID 30185520, PMID 30876830, PMID 31362741, PMID 31613151, PMID 31798645, PMID 31999203, PMID 32101904, PMID 32338094, PMID 32469092, PMID 32612738, PMID 32729038, PMID 33027187, PMID 33220516, PMID 33263024, PMID 33359443, PMID 34048497, PMID 34271216, PMID 34774528, PMID 34779751, PMID 35177038
2018 (2), 2017 (1), 2023 (1), 2025 (1), R01HL133664 (1)